Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network.
In this issue of JCP, Zhou and colleagues review and integrate placebo-controlled efficacy trials of medications for treatment-resistant depression (TRD) to compare efficacy in a meta-analysis. They conclude that, among 11 augmentation options for TRD, aripiprazole and quetiapine have the most robust evidence for efficacy, with the caveats that these treatments carry substantial risks of adverse events and no long-term data are available. In the absence of direct comparisons, this exercise highlights the formidable challenges that clinicians face when making decisions.
Department of Psychiatry, Massachusetts General Hospital, 50 Stanford St, 5th Floor, Boston, MA 02114 anierenberg@partners.org.
Andrew A
AA
Nierenberg
Louisa
L
Sylvia
Allen
A
Doederlein
Susan
S
Edgman-Levitan
Alies
A
Muskin
Lucinda
L
Jewell
Muffy
M
Walker
Dan
D
Goodman
Massoud
M
Farahbakhsh
Casey
C
Hearing
Roberta
R
Tovey
Thilo
T
Deckersbach
D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D061218:Depressive Disorder, Treatment-Resistant / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010342:Patient Acceptance of Health Care / Q000523:psychology*
D000928:Antidepressive Agents